spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

MedPharm accelerates strategy to broaden service offering into commercial manufacturing


MedPharm Ltd, a leading contract provider of topical and transdermal product design and development services, has announced two new appointments to its Board to support plans to grow its commercial manufacturing services.

The new members, Paul Johnson and Norman Barras, will be joining MedPharm’s board following a rigorous search, aimed at deepening the company’s expertise in pharmaceutical development and manufacturing services.

Performance tests are an integral part of any formulation development programme at MedPharm. They are used strategically throughout the development process to mitigate development risks and failures due to inadequate product performance. MedPharm’s proven and unique models de-risk the development process and greatly increase the probability of success.

“MedPharm has a clear strategy to broaden its services; particularly into the later stage development and commercial manufacturing of topical products”, stated President & CEO Eugene Ciolfi. ‘Paul and Norman bring a wealth of experience which will be highly beneficial to MedPharm as we expand our services offerings. Their deep understanding of integrating pharmaceutical operations, including commercial manufacture, will be invaluable to the business as we expand into these new markets’.

Paul Johnson is an Operating Partner with Ampersand Capital, which made a strategic investment in MedPharm in early 2018. Paul previously served as President and CEO of DPT and Renaissance Pharmaceuticals, a leading, high growth, topicals CDMO and specialty generics company, which was sold to Mylan in 2016. He has over 30 years of broad and diverse experience in the pharmaceutical industry.
Norman Barras is an independent consultant with an extensive career in pharmaceutical research, contract manufacturing and development which included senior leadership roles at Patheon, Penn/PCI Pharmaceuticals and Lonza Biologics. He has over 30 years’ experience in the pharmaceutical industry.

For more information on MedPharm and its services, please visit:
www.medpharm.com

ENDS

For further information, images and interview opportunities, please contact Celine Goodier at ramarketing: celine@ramarketingpr.com| +44 (0)191 222 1242 or www.ramarketingpr.com

NOTES TO EDITORS

About MedPharm
MedPharm Ltd. is a leading, global provider of contract topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through the use of proprietary, industry-leading performance testing models. Well-established as a global leader in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm also offers innovative solutions for ophthalmic and airway preparations. These solutions are recognised for their scientific rigor by regulators and investors. MedPharm has fully established R&D centres in the US and UK and GMP clinical manufacturing at its global headquarters facility in Guildford, UK. For more information visit our website www.medpharm.com.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>


White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals – gaining strong, new industry contacts and building on existing ones.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement